Dec 6 (Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc 's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus.
Dec 6 (Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc 's Sovaldi, also known as sofosbuvir, as a treatment for chronic infection with the liver-destroying hepatitis C virus.
The FDA approves Gilead 's ( GILD ) sofosbuvir for HCV. One FDA official calls this "a significant shift in the treatment paradigm for some patients with chronic
Shares of Gilead Sciences ( GILD +1% ) are trading higher on the session. Helping the cause is GMP Securities, where analysts have upgraded the stock to Buy from Hold. Post your comment!
has filed two lawsuits against Gilead Sciences ( GILD -0.7% ): A patent infringement ..... Brian Abrahams, the impact on GILD is likely to be minimal . "Though ..... IDIX another means of challenging GILD , we expect the process to be lengthy
CELG ) at Neutral. Repros Therapeutics ( RPRX ) initiated at Overweight at Piper. Price target is $26. Piper starts Gilead ( GILD ) at Overweight. Price target is $91. Incyte ( INCY ) initiated at Overweight at Piper. Price target is $56. Piper starts
By James Banjo : Gilead Sciences ( GILD ), a biopharmaceutical research ..... indeed has traits of a growth stock. Gilead Sciences reported $9.7 billion in sales ..... outstanding financial performer. GILD 's third-quarter 2013 results
to date pushed two drug candidates into the clinic. The first drug candidate is CMX001, a lipid-conjugate of cidofovir (brand name Vistide), manufactured by Gilead Sciences ( GILD ). CMX001 has successfully completed Complete Story »
sellers decreased their holdings by more than 10%. Gilead Sciences ( GILD ) discovers, develops, and commercializes human ..... selling during the last 30 days Here is a table of Gilead 's insider-trading activity during the last 30
February 28, 2014, as stated by management on the November 7 Pharmacyclics conference call . The delay is giving Gilead Sciences ' ( GILD ) CLL candidate idelalisib time to catch up in the race. Idealisib's Phase 3 trial was recently stopped early